-+ 0.00%
-+ 0.00%
-+ 0.00%

Needham Reiterates Buy on OncoCyte, Maintains $4.25 Price Target

Benzinga·05/13/2025 11:52:03
Listen to the news
Needham analyst Mike Matson reiterates OncoCyte (NASDAQ:OCX) with a Buy and maintains $4.25 price target.